HeyJaredCardio Trial Files
Free, bimonthly newsletter that summarizes the most significant, practice-changing cardiology randomized controlled trials, straight to your inbox.
- Indexed issues, last 90 days
- 3
- Latest publication
- Sep 24, 2026
- Audience
- Checking…
- Earliest in this view
- Jul 30, 2026
Latest issues
Cardio Trial Files Throwback Thursday: Patisiran in ATTR Amyloidosis, TAVR vs. SAVR, and Stopping Aspirin After Stenting (opens the original)
Read excerpt
Patisiran Treatment in Patients with Transthyretin Cardiac AmyloidosisMaurer MS et al. NEJM (October 2023)Bottom Line: This randomized, open-label, non-inferiority trial included 2850 patients with acute coronary syndrome who underwent drug-eluting stent implantation at 24 centres in South Korea. The patients were randomly assigned to receive either ticagrelor monotherapy (90 mg twice daily) after <1 month of DAPT (n=1426) or 12 months of ticagrelor-based DAPT (n=1424). The primary endpoint was
Cardio Trial Files: Mavacamten in HOCM, Enlicitide vs. Oral Nonstatins, and Weight Loss in AFib (opens the original)
Read excerpt
Mavacamten in Adolescents with Obstructive Hypertrophic CardiomyopathyRossano JW et al. NEJM (March 2026)Bottom Line: This phase 3, double-blind, randomized, placebo-controlled trial evaluated the efficacy and safety of mavacamten in 44 symptomatic adolescents (12 to <18 years) with obstructive hypertrophic cardiomyopathy. Participants were randomly assigned to receive either mavacamten or placebo for 28 weeks. The primary outcome was the change in left ventricular outflow tract pressure gradien
Cardio Trial Files Throwback Thursday: Dapa in MI, Edoxaban in AFib, and Lepodisiran Tolerability (opens the original)
Read excerpt
Dapagliflozin in Myocardial Infarction without Diabetes or Heart FailureJames S et al. NEJM Evidence (November 2023)Bottom Line: This international, registry-based, randomized, double-blind trial enrolled 4,017 patients without prior diabetes or chronic heart failure who presented with acute myocardial infarction and impaired left ventricular systolic function to compare dapagliflozin 10 mg daily with placebo. The primary outcome was a hierarchical composite of death, hospitalization for heart f
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
No verified audience measurement yet.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.